Design, development, and validation of an end-user assay for low-cost, on-site, and rapid quantification of COVID-19 antigen and antibodies

设计、开发和验证最终用户检测方法，以低成本、现场快速定量 COVID-19 抗原和抗体

• 批准号: 570531-2021
• 负责人: Tabatabaei, NimaN
• 金额: $ 10.64万
• 依托单位: York University
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=760075
• 关键词: Design; development; validation; end; user

Introduction of COVID-19 vaccines in late 2020 created hope for overcoming the pandemic, but soon it became clear that mankind is expected to struggle with SARS-CoV-2 until a time when world population (including children) is mass immunized. Reaching this goal is expected to take several years during which: 1) the vaccinated population need to maintain their immunity; 2) more effective approaches (e.g., low-cost, accessible, accurate) should be implemented for earlier identification of infected individuals to prevent future infection peaks. Successful implementation of these two objectives requires population-wide serological studies which in practice can only be realized through low-cost and widely accessible technologies for sensitive detection and quantification of COVID-19 antibodies (Ab) and virus/antigen (Ag). Such technologies currently do not exist.The goal of this partnership is to design, develop, and validate a low-cost end-user rapid test technology for sensitive detection and quantification of COVID-19 antibodies and antigen/virus. The engineering knowledge and innovative technologies generated through this project will enable the government of Canada to implement large scale, accessible and equitable quantitative testing through which well-educated decisions and policies can be made. For Canadian businesses, proposed project provides employers with low-cost, yet accurate, solutions to ensure workplace safety either through sensitive detection of infected individuals, or through monitoring of antibody levels of vaccinated employees. In terms of economy, proposed project aims to solve an existing worldwide challenge with significant socio-economic impact. Given the track record of partner in development and global marketing of rapid tests, the technology to be developed in Canada is expected to make significant contribution to Canadian economy through creation of jobs and global sales.

2020年末引入Covid-19-19疫苗为克服大流行带来了希望，但很快就显然人类有望与SARS-COV-2斗争，直到世界人口（包括儿童）进行大规模免疫接种。预计达到这一目标将需要几年的时间：1）接种疫苗的人口需要维持其免疫力； 2）应实施更有效的方法（例如，低成本，可访问，准确），以较早地识别受感染的个体，以防止未来的感染峰。这两个目标的成功实施需要范围内的血清学研究，在实践中，只能通过低成本且广泛可访问的技术来实现敏感检测和量化covid-19抗体（AB）和病毒/抗原（AG）的敏感检测和定量。此类技术目前尚不存在。该合作伙伴关系的目的是设计，开发和验证低成本的最终用户快速测试技术，用于敏感的检测和量化COVID-19抗体和抗原/病毒。通过该项目产生的工程知识和创新技术将使加拿大政府能够实施大规模，可访问且公平的定量测试，通过这些测试可以通过，通过这些测试，可以做出良好教育的决策和政策。对于加拿大企业，拟议的项目为雇主提供了低成本但准确的解决方案，以通过对感染者的敏感检测或通过监测接种疫苗的员工的抗体水平来确保工作场所安全。在经济方面，拟议项目旨在解决现有的全球挑战，并具有重大的社会经济影响。鉴于合作伙伴在开发和全球快速测试中的记录，预计在加拿大开发的技术将通过创造就业机会和全球销售来为加拿大经济做出重大贡献。